Humacyte Secures $46.8M in Highly Dilutive 47.6M-Share Offering at $1.05
HUMA sits 97% above its 52-week low of $0.547 on elevated volume (3.7× avg).
Summary
Humacyte has formally entered an underwriting agreement for a public offering of 47.6 million common shares at $1.05 each, expected to net approximately $46.8 million. This follows the shareholder approval on June 9th to increase authorized common stock and the pricing announcement earlier today. The offering is highly dilutive, representing a significant portion of the company's market capitalization, and comes after a history of dilutive raises and a going concern warning. While providing critical capital for operations, this raise underscores the company's ongoing need for financing despite recent positive Phase 3 trial results.
At the time of this announcement, HUMA was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $239.8M. The 52-week trading range was $0.55 to $2.84. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.